- Novo Nordisk has announced plans to construct a $4.1 billion factory in Clayton, North Carolina, aimed at addressing shortages of its popular weight-loss and diabetes drugs, Wegovy and Ozempic. This move comes amidst widespread patient difficulties in accessing GLP-1 injectable medications, an issue also affecting competitors like Eli Lilly. The 1.4 million-square-foot facility is set to double Novo Nordisk’s presence in North Carolina and is expected to create 1,000 new jobs by 2029, supplementing the current 2,500 roles in the area. CEO Lars Fruergaard Jørgensen emphasized the company’s commitment to expanding global production to meet the needs of millions more patients with chronic diseases in the future. This expansion reflects Novo Nordisk’s strategy to strengthen supply chains and alleviate medication shortages in the long term. (Articles here and here)
July 16, 2024
Life Sciences | Tea Leaves